BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067]
URL: https://www.wjgnet.com/1007-9327/full/v15/i17/2067.htm
Number Citing Articles
1
Maria Rojas-Feria, Mohammed Eslam, Manuel Castro-Fernández, Pedro Guerrero, Jose-Luis Larraona-Moreno, Manuel Romero-Gómez. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapyJournal of Crohn's and Colitis 2011; 5(6): 608 doi: 10.1016/j.crohns.2011.04.015
2
Gert Van Assche, James D Lewis, Gary R Lichtenstein, Edward V Loftus, Qin Ouyang, Julian Panes, Corey A Siegel, William J Sandborn, Simon P L Travis, Jean-Frederic Colombel. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: SafetyAmerican Journal of Gastroenterology 2011; 106(9): 1594 doi: 10.1038/ajg.2011.211
3
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis. Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?Intestinal Research 2021; 19(4): 461 doi: 10.5217/ir.2020.00042
4
Manuela Marzo, Carla Felice, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi. Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel DiseaseClinical Medicine Insights: Therapeutics 2011; 3: CMT.S1978 doi: 10.4137/CMT.S1978
5
Giovanni Casella, Vincenzo Villanacci, Camillo Di Bella, Elisabetta Antonelli, Vittorio Baldini, Gabrio Bassotti. Pulmonary diseases associated with inflammatory bowel diseasesJournal of Crohn's and Colitis 2010; 4(4): 384 doi: 10.1016/j.crohns.2010.02.005
6
Carissa M. Thomas, Delphine M. A. Saulnier, Jennifer K. Spinler, Peera Hemarajata, Chunxu Gao, Sara E. Jones, Ashley Grimm, Miriam A. Balderas, Matthew D. Burstein, Christina Morra, Daniel Roeth, Markus Kalkum, James Versalovic. FolC2‐mediated folate metabolism contributes to suppression of inflammation by probioticLactobacillus reuteriMicrobiologyOpen 2016; 5(5): 802 doi: 10.1002/mbo3.371
7
Tolga Sursal, Deborah J. Stearns-Kurosawa, Kiyoshi Itagaki, Sun-Young Oh, Shiqin Sun, Shinichiro Kurosawa, Carl J. Hauser. Plasma Bacterial and Mitochondrial DNA Distinguish Bacterial Sepsis From Sterile Systemic Inflammatory Response Syndrome and Quantify Inflammatory Tissue Injury in Nonhuman PrimatesShock 2013; 39(1): 55 doi: 10.1097/SHK.0b013e318276f4ca
8
Isabelle Cleynen, Séverine Vermeire. Paradoxical inflammation induced by anti-TNF agents in patients with IBDNature Reviews Gastroenterology & Hepatology 2012; 9(9): 496 doi: 10.1038/nrgastro.2012.125
9
Halina Cichoż-Lach, Agata Michalak, Maria Kopertowska-Majchrzak, Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Waszak, Renata Talar-Wojnarowska, Hubert Zatorski, Anna Solarska-Półchłopek, Jarosław Chmielnicki, Rafał Filip, Anna Pękala, Maria Janiak, Krzysztof Skrobot, Ewa Kasińska, Michał Krogulecki, Piotr Królikowski, Maria Kłopocka, Ariel Liebert, Elżbieta Poniewierka, Izabela Smoła, Anita Gąsiorowska, Aleksandra Kaczka, Joanna Wypych, Krzysztof Wojciechowski, Szymon Drygała, Edyta Zagórowicz. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study)Therapeutic Advances in Gastroenterology 2021; 14: 175628482110364 doi: 10.1177/17562848211036456
10
J. Présumey, G. Salzano, G. Courties, M. Shires, F. Ponchel, C. Jorgensen, F. Apparailly, G. De Rosa. PLGA microspheres encapsulating siRNA anti-TNFalpha: Efficient RNAi-mediated treatment of arthritic jointsEuropean Journal of Pharmaceutics and Biopharmaceutics 2012; 82(3): 457 doi: 10.1016/j.ejpb.2012.07.021
11
Xue-Liang Jiang, Hui-Fei Cui, Jing Gao, Hua Fan. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative ColitisJournal of Clinical Gastroenterology 2015; 49(7): 582 doi: 10.1097/MCG.0000000000000319
12
Xiao-Qing Ji, Li-Xia Wang, De-Gan Lu. Pulmonary manifestations of inflammatory bowel diseaseWorld Journal of Gastroenterology 2014; 20(37): 13501-13511 doi: 10.3748/wjg.v20.i37.13501
13
Z. Arora, B. Shen. Biological therapy for ulcerative colitisGastroenterology Report 2015; 3(2): 103 doi: 10.1093/gastro/gou070
14
A. W. G. Waugh, S. Garg, K. Matic, L. Gramlich, C. Wong, D. C. Sadowski, M. Millan, R. Bailey, D. Todoruk, R. Cherry, C. W. Teshima, L. Dieleman, R. N. Fedorak. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohortAlimentary Pharmacology & Therapeutics 2010; 32(9): 1129 doi: 10.1111/j.1365-2036.2010.04446.x
15
Jeff Chang, Rupert WL Leong. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposureExpert Opinion on Biological Therapy 2014; 14(1): 27 doi: 10.1517/14712598.2014.853738
16
Shivaram Bhat, Divyesh Sharma, Pauline Doherty, Tony C.K. Tham, Grant R. Caddy. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?Inflammatory Bowel Diseases 2010; 16(11): 1922 doi: 10.1002/ibd.21279
17
Bo Xiao, Qiubing Chen, Zhan Zhang, Lixin Wang, Yuejun Kang, Timothy Denning, Didier Merlin. TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitisJournal of Controlled Release 2018; 287: 235 doi: 10.1016/j.jconrel.2018.08.021
18
Ernst Beinder, Thorsten Fischer, Dieter Grab, Thomas Grubert, Peer Hantschmann, Franz Kainer, Ralph Kästner, Christina Kentenich, Walter Klockenbusch, Reinhard Kopp, Frank Lammert, Frank Louwen, Ioannis Mylonas, Stephanie Pildner von Steinburg, Werner Rath, Ute M. Schäfer-Graf, Ekkehard Schleußner, Ralf Schmitz, Maximilian Sohn, Heinrich Otto Steitz. Facharzt Geburtsmedizin2012; : 369 doi: 10.1016/B978-3-437-23751-5.10017-2
19
Xiang Xue, Sadeesh Ramakrishnan, Erik Anderson, Matthew Taylor, Ellen M. Zimmermann, Jason R. Spence, Sha Huang, Joel K. Greenson, Yatrik M. Shah. Endothelial PAS Domain Protein 1 Activates the Inflammatory Response in the Intestinal Epithelium to Promote Colitis in MiceGastroenterology 2013; 145(4): 831 doi: 10.1053/j.gastro.2013.07.010
20
Sherman Picardo, Kenji So, Kannan Venugopal. Anti‐TNF‐induced lupus in patients with inflammatory bowel diseaseJGH Open 2020; 4(3): 507 doi: 10.1002/jgh3.12291
21
N Plevris, C S Chuah, R M Allen, I D Arnott, P N Brennan, S Chaudhary, A M D Churchhouse, S Din, E Donoghue, D R Gaya, M Groome, H M Jafferbhoy, P W Jenkinson, W L Lam, M Lyons, J C Macdonald, M MacMaster, C Mowat, G D Naismith, L F Potts, E Saffouri, J P Seenan, A Sengupta, P Shasi, D I Sutherland, J A Todd, J Veryan, A J M Watson, D A Watts, G R Jones, C W Lees. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab CohortJournal of Crohn's and Colitis 2019; 13(9): 1111 doi: 10.1093/ecco-jcc/jjz042
22
Christina Kriegel, Mansoor M Amiji. Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel DiseaseClinical and Translational Gastroenterology 2011; 2(3): e2 doi: 10.1038/ctg.2011.1
23
Jatinder P. Ahluwalia. Immunotherapy in Inflammatory Bowel DiseaseMedical Clinics of North America 2012; 96(3): 525 doi: 10.1016/j.mcna.2012.04.009
24
Current awareness: Pharmacoepidemiology and drug safetyPharmacoepidemiology and Drug Safety 2009; 18(12): i doi: 10.1002/pds.1655
25
Ellen A. Lipstein, Maria T. Britto. Evolution of Pediatric Chronic Disease Treatment DecisionsMedical Decision Making 2015; 35(6): 703 doi: 10.1177/0272989X15581805
26
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe, William J Sandborn. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology 2012; 107(9): 1409 doi: 10.1038/ajg.2012.218
27
Victor Klimyuk, Gregory Pogue, Stefan Herz, John Butler, Hugh Haydon. Plant Viral VectorsCurrent Topics in Microbiology and Immunology 2012; 375: 127 doi: 10.1007/82_2012_212
28
Raymond K. Cross. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative ColitisInflammatory Bowel Diseases 2017; 23(10): 1689 doi: 10.1097/MIB.0000000000001261
29
Giorgia Bodini, Maria Giulia Demarzo, Margherita Saracco, Claudia Coppo, Costanza De Maria, Isabella Baldissarro, Edoardo Savarino, Vincenzo Savarino, Edoardo G. Giannini. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology 2019; 54(10): 1220 doi: 10.1080/00365521.2019.1666914
30
Sebastian Strobel, Maria T. Abreu. Biologic Therapy in Inflammatory Bowel Disease—A Gastrointestinal PerspectiveSeminars in Colon and Rectal Surgery 2012; 23(2): 81 doi: 10.1053/j.scrs.2012.02.007
31
Silvio Danese, Kavitha Subramaniam, Jan Van Zyl, Shashi Adsul, Dirk Lindner, Jeannine Roth, Séverine Vermeire. Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programmeAlimentary Pharmacology & Therapeutics 2021; 53(2): 265 doi: 10.1111/apt.16160
32
Husain Attarwala, Mansoor Amiji. Handbook of Polyester Drug Delivery Systems2016; : 417 doi: 10.1201/b20045-14
33
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 UpdateCurrent Gastroenterology Reports 2020; 22(9) doi: 10.1007/s11894-020-00781-3
34
Dejun Cui, Guomei Huang, Daping Yang, Bo Huang, Bangquan An. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: A systematic review and meta-analysis of randomized controlled trialsClinics and Research in Hepatology and Gastroenterology 2013; 37(5): 507 doi: 10.1016/j.clinre.2012.12.004
35
Ellen A. Lipstein, Cassandra M. Dodds, Daniel J. Lovell, Lee A. Denson, Maria T. Britto. Making decisions about chronic disease treatment: a comparison of parents and their adolescent childrenHealth Expectations 2016; 19(3): 716 doi: 10.1111/hex.12210
36
Roberta Elisa Rossi, Ioanna Parisi, Edward John Despott, Andrew Kenneth Burroughs, James O'Beirne, Dario Conte, Mark Ian Hamilton, Charles Daniel Murray. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for managementWorld Journal of Gastroenterology 2014; 20(46): 17352-17359 doi: 10.3748/wjg.v20.i46.17352
37
Min Kyoung Cho, Mi Kyung Park, Shin Ae Kang, Seon Hee Choi, Soon Cheol Ahn, Hak Sun Yu. Trichinella spiralis Infection Suppressed Gut Inflammation with CD4+CD25+Foxp3+T Cell RecruitmentThe Korean Journal of Parasitology 2012; 50(4): 385 doi: 10.3347/kjp.2012.50.4.385
38
Steffen Dan-Nielsen, Vibeke Wewer, Anders Paerregaard, Lars F. Hansen, Rasmus G. Nielsen, Aksel Lange, Christian Jakobsen. Does Infliximab Prevent Colectomy in Acute and Chronic Active Ulcerative Colitis?Journal of Pediatric Gastroenterology & Nutrition 2014; 58(6): 768 doi: 10.1097/MPG.0000000000000340
39
Paulina Núñez F, Rodrigo Quera, Constanza Bay, Fabiola Castro, Gabriel Mezzano. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel DiseaseJournal of Crohn's and Colitis 2022; 16(7): 1168 doi: 10.1093/ecco-jcc/jjac013
40
Laura Jansen, Xander G Vos, Mark Löwenberg. Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitisWorld Journal of Clinical Cases 2016; 4(2): 60-62 doi: 10.12998/wjcc.v4.i2.60
41
Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuki Toyokawa, Makoto Tanaka, Yuma Hotta, Kazuhiro Kamada, Takeshi Ishikawa, Hideyuki Konishi, Mitsuo Kishimoto, Yuji Naito, Yoshito Itoh. Increased mucosal IL-12 expression is associated with relapse of ulcerative colitisBMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01709-5
42
Tripti Khare, Sushesh Srivatsa Palakurthi, Brijesh M. Shah, Srinath Palakurthi, Sharad Khare. Natural Product-Based Nanomedicine in Treatment of Inflammatory Bowel DiseaseInternational Journal of Molecular Sciences 2020; 21(11): 3956 doi: 10.3390/ijms21113956
43
Fanny Giron, Anna Pastó, Ennio Tasciotti, Bincy P Abraham. Nanotechnology in the Treatment of Inflammatory Bowel DiseaseInflammatory Bowel Diseases 2019; 25(12): 1871 doi: 10.1093/ibd/izz205
44
Martin Luchtefeld, Tarek Jalouta. Anorectal Disease2016; : 127 doi: 10.1007/978-3-319-23147-1_6
45
Sam C. Nalle, Jerrold R. Turner. Biology and Regulation of Blood-Tissue BarriersAdvances in Experimental Medicine and Biology 2013; 763: 105 doi: 10.1007/978-1-4614-4711-5_5
46
Honghui Zhou, Yan Xu, Amarnath Sharma. Pharmaceutical Biotechnology2019; : 557 doi: 10.1007/978-3-030-00710-2_26
47
Honghui Zhou, Zhenhua Xu, Mary Ann Mascelli, Hugh M. Davis. Pharmaceutical Biotechnology2013; : 393 doi: 10.1007/978-1-4614-6486-0_20
48
Husain Attarwala, Murui Han, Jonghan Kim, Mansoor Amiji. Oral nucleic acid therapy using multicompartmental delivery systemsWIREs Nanomedicine and Nanobiotechnology 2018; 10(2) doi: 10.1002/wnan.1478
49
Jeffrey B. Brown, Paul Cheresh, Zheng Zhang, Hyunji Ryu, Elizabeth Managlia, Terrence A. Barrett. P-Selectin Glycoprotein Ligand-1 Is Needed for Sequential Recruitment of T-Helper 1 (Th1) and Local Generation of Th17 T Cells in Dextran Sodium Sulfate (DSS) ColitisInflammatory Bowel Diseases 2012; 18(2): 323 doi: 10.1002/ibd.21779
50
Chunbai He, Lichen Yin, Yudong Song, Cui Tang, Chunhua Yin. Optimization of multifunctional chitosan–siRNA nanoparticles for oral delivery applications, targeting TNF-α silencing in ratsActa Biomaterialia 2015; 17: 98 doi: 10.1016/j.actbio.2015.01.041
51
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Wayne Langholff, Anil Londhe, William J Sandborn. Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ RegistryAmerican Journal of Gastroenterology 2014; 109(2): 212 doi: 10.1038/ajg.2013.441
52
Kinga Majchrzak, Jakub Fichna. Biologic Therapy in Crohn’s Disease–What We Have Learnt So FarCurrent Drug Targets 2020; 21(8): 792 doi: 10.2174/1389450121666191218123203
53
Koji Sono, Akihiro Yamada, Yasushi Yoshimatsu, Nobuo Takada, Yasuo Suzuki. Factors associated with the loss of response to infliximab in patients with Crohn’s diseaseCytokine 2012; 59(2): 410 doi: 10.1016/j.cyto.2012.04.026
54
Angelo V. Marzano, Alessandro Borghi, Pier Luigi Meroni, Carlo Crosti, Massimo Cugno. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapyAutoimmunity 2014; 47(3): 146 doi: 10.3109/08916934.2013.873414
55
Palpandi Pandi, Anjali Jain, Saka Raju, Wahid Khan. Therapeutic approaches for the delivery of TNF-α siRNATherapeutic Delivery 2017; 8(5): 343 doi: 10.4155/tde-2017-0011
56
Sung Won Jang, Min Kyoung Cho, Mi Kyung Park, Shin Ae Kang, Byoung-Kuk Na, Soon Cheol Ahn, Dong-Hee Kim, Hak Sun Yu. Parasitic Helminth Cystatin Inhibits DSS-Induced Intestinal Inflammation Via IL-10+F4/80+Macrophage RecruitmentThe Korean Journal of Parasitology 2011; 49(3): 245 doi: 10.3347/kjp.2011.49.3.245
57
Christina Kriegel, Husain Attarwala, Mansoor Amiji. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tractAdvanced Drug Delivery Reviews 2013; 65(6): 891 doi: 10.1016/j.addr.2012.11.003
58
Ellen A. Lipstein, Daniel J. Lovell, Lee A. Denson, David W. Moser, Shehzad A. Saeed, Cassandra M. Dodds, Maria T. Britto. Parents’ Information Needs in Tumor Necrosis Factor-α Inhibitor Treatment DecisionsJournal of Pediatric Gastroenterology & Nutrition 2013; 56(3): 244 doi: 10.1097/MPG.0b013e31827496c3
59
H. Sales-Campos, P.J. Basso, V.B.F. Alves, M.T.C. Fonseca, G. Bonfá, V. Nardini, C.R.B. Cardoso. Classical and recent advances in the treatment of inflammatory bowel diseasesBrazilian Journal of Medical and Biological Research 2015; 48(2): 96 doi: 10.1590/1414-431x20143774
60
Fernando Magro, Francisco Portela. Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha TherapiesBioDrugs 2010; 24: 3 doi: 10.2165/11586290-000000000-00000
61
Bernard Bizzini, Béatrice Drouet, Daniel Zagury, Marc Abitbol, Arsène Burny, Marie-Christophe Boissier. Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancerImmunotherapy 2010; 2(3): 347 doi: 10.2217/imt.10.16
62
Laura Janssen, Mariëlle Romberg-Camps, Ad van Bodegraven, Jeoffrey Haans, Michèl Aquarius, Paul Boekema, Tamara Munnecom, Lloyd Brandts, Manuela Joore, Adrian Masclee, D Jonkers, M Pierik. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trialBMJ Open 2021; 11(5): e042885 doi: 10.1136/bmjopen-2020-042885
63
S. He, T. Li, H. Chen, W. Ma, Q. Yao, H. Yang, H. Wang, F. Wang, C. Zhao, P. Yang. CD14+ cell-derived IL-29 modulates proinflammatory cytokine production in patients with allergic airway inflammationAllergy 2011; 66(2): 238 doi: 10.1111/j.1398-9995.2010.02455.x
64
Lucianna Motta Correia, Danielle Queiroz Bonilha, Juliana Dantas Ramos, Orlando Ambrogini, Sender Jankiel Miszputen. Treatment of inflammatory bowel disease and pregnancy: a review of the literatureArquivos de Gastroenterologia 2010; 47(2): 197 doi: 10.1590/S0004-28032010000200016
65
Thomas W. Lee, Richard N. Fedorak. Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice PharmacologyGastroenterology Clinics of North America 2010; 39(3): 543 doi: 10.1016/j.gtc.2010.08.018
66
Gregory P. Pogue, Fakhrieh Vojdani, Kenneth E. Palmer, Ernie Hiatt, Steve Hume, Jim Phelps, Lori Long, Natasha Bohorova, Do Kim, Michael Pauly, Jesus Velasco, Kevin Whaley, Larry Zeitlin, Stephen J. Garger, Earl White, Yun Bai, Hugh Haydon, Barry Bratcher. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systemsPlant Biotechnology Journal 2010; 8(5): 638 doi: 10.1111/j.1467-7652.2009.00495.x
67
Isabel Nawroth, Jan Alsner, Mark A. Behlke, Flemming Besenbacher, Jens Overgaard, Kenneth A. Howard, Jørgen Kjems. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFα prevents radiation-induced fibrosisRadiotherapy and Oncology 2010; 97(1): 143 doi: 10.1016/j.radonc.2010.09.010
68
Ryoki Takahashi, Takayasu Noguchi, Yoko Mizoguchi, Tadashi Shimoyama, Teruko Nakazawa, Tohru Ikuta. A Synbiotic with Tumor Necrosis Factor-αInhibitory Activity Ameliorates Experimental Jejunoileal Mucosal InjuryBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/9184093
69
Cristhiane Favero de Aguiar, Angela Castoldi, Vinícius Andrade-Oliveira, Aline Ignacio, Flávia Franco da Cunha, Raphael José Ferreira Felizardo, Ênio José Bassi, Niels Olsen Saraiva Câmara, Danilo Candido de Almeida. Mesenchymal stromal cells modulate gut inflammation in experimental colitisInflammopharmacology 2018; 26(1): 251 doi: 10.1007/s10787-017-0404-6
70
Christine L. Schuler, Cassandra Dodds, Kevin A. Hommel, Richard F. Ittenbach, Lee A. Denson, Ellen A. Lipstein. Shared decision making in IBD: A novel approach to trial consent and timingContemporary Clinical Trials Communications 2019; 16: 100447 doi: 10.1016/j.conctc.2019.100447